167 related articles for article (PubMed ID: 38662353)
1. When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario.
Danesin N; Scapinello G; Del Prete D; Naso E; Berno T; Visentin A; Bonaldi L; Martines A; Bertorelle R; Vianello F; Gurrieri C; Zambello R; Castellani C; Fedrigo M; Rizzo S; Angelini A; Trentin L; Piazza F
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2062. PubMed ID: 38662353
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder.
Nie G; Sun L; Zhang C; Yuan Y; Mao H; Wang Z; Li J; Duan S; Xing C; Zhang B
Front Immunol; 2022; 13():903315. PubMed ID: 36172352
[TBL] [Abstract][Full Text] [Related]
3. Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients.
Chauvet S; Bridoux F; Ecotière L; Javaugue V; Sirac C; Arnulf B; Thierry A; Quellard N; Milin S; Bender S; Goujon JM; Jaccard A; Fermand JP; Touchard G
Am J Kidney Dis; 2015 Nov; 66(5):756-67. PubMed ID: 25987261
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
5. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
[TBL] [Abstract][Full Text] [Related]
6. Renal involvement in Waldenström's macroglobulinemia: case report and review of literature.
Salviani C; Guido G; Serriello I; Giannakakis K; Rocca AR
Ren Fail; 2014 Feb; 36(1):114-8. PubMed ID: 24059636
[TBL] [Abstract][Full Text] [Related]
7. Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.
Higgins L; Nasr SH; Said SM; Kapoor P; Dingli D; King RL; Rajkumar SV; Kyle RA; Kourelis T; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Ansell SM; Gonsalves WI; Thompson CA; Fervenza FC; Zand L; Hwa YL; Jevremovic D; Shi M; Leung N
Clin J Am Soc Nephrol; 2018 Jul; 13(7):1037-1046. PubMed ID: 29848505
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M
J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775
[TBL] [Abstract][Full Text] [Related]
9. Recovery of kidney function by rituximab-based therapy in a patient with Waldenström's macroglobulinemia-related nephropathy presenting cast nephropathy and interstitial lymphocytic infiltration.
Miwa M; Sakao Y; Ishigaki S; Ono M; Fujikura T; Yasuda H; Suzuki H; Kato A; Nagata Y; Shigeno K; Nakamura S; Ohnishi K; Fujigaki Y
Intern Med; 2012; 51(13):1725-30. PubMed ID: 22790134
[TBL] [Abstract][Full Text] [Related]
10. Renal MALT lymphoma associated with Waldenström macroglobulinemia.
Chi PJ; Pei SN; Huang TL; Huang SC; Ng HY; Lee CT
J Formos Med Assoc; 2014 Apr; 113(4):255-7. PubMed ID: 24685302
[TBL] [Abstract][Full Text] [Related]
11. Report of consensus panel 1 from the 11
Buske C; Castillo JJ; Abeykoon JP; Advani R; Arulogun SO; Branagan AR; Cao X; D'Sa S; Hou J; Kapoor P; Kastritis E; Kersten MJ; LeBlond V; Leiba M; Matous JV; Paludo J; Qiu L; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Varettoni M; Vos JM; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Trotman J
Semin Hematol; 2023 Mar; 60(2):73-79. PubMed ID: 37099027
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia.
Izzedine H; Bourry E; Amrouche L; Brocheriou I; Uzunov M; Capron F; Leblond V; Deray G
Int J Hematol; 2009 Mar; 89(2):218-222. PubMed ID: 19156501
[TBL] [Abstract][Full Text] [Related]
13. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
Kapoor P; Paludo J; Abeykoon JP
Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
15. Waldenstrom macroglobulinemia with CD5+ expression presented as cryoglobulinemic glomerulonephropathy: a case report.
Kim YL; Gong SJ; Hwang YH; Joo JE; Cho YU; Lee JA; Sung SA; Lee SY; Kim NY
J Korean Med Sci; 2011 Jun; 26(6):824-8. PubMed ID: 21655071
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Carulli G; Ciancia EM; Azzarà A; Ottaviano V; Grassi S; Ciabatti E; Ferreri MI; Rocco M; Marini A; Petrini M
J Clin Exp Hematop; 2013; 53(1):29-36. PubMed ID: 23801131
[TBL] [Abstract][Full Text] [Related]
17. Kidney diseases associated with Waldenström macroglobulinemia.
Uppal NN; Monga D; Vernace MA; Mehtabdin K; Shah HH; Bijol V; Jhaveri KD
Nephrol Dial Transplant; 2019 Oct; 34(10):1644-1652. PubMed ID: 30380110
[TBL] [Abstract][Full Text] [Related]
18. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
[TBL] [Abstract][Full Text] [Related]
19. Waldenstrom macroglobulinemia: prognosis and management.
Oza A; Rajkumar SV
Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
